A Louisville Man’s Fight for Cancer Care, and What We Can All Learn
By Frank M. Mungo, Attorney at Law
AppealHealthcare.com
Tracy Pike was a hardworking maintenance man from Louisville, Kentucky. He was also a husband, a father, and a man who had already once beaten stage IV stomach cancer. But when his cancer returned after 12 years of remission, he faced a deadly disease and an unexpected adversary: his health insurance company.
Gretchen Morgenson first reported Pike’s story in NBC News on December 27, 2024. Morgenson’s reporting revealed that Pike’s doctors recommended a high-risk surgery and chemotherapy at MD Anderson Cancer Center in Houston. They believed it could prolong his life or possibly save it. But his insurer, Blue Cross and Blue Shield of Illinois, denied coverage because the procedure was “experimental.” Pike died in January 2024.
It did not have to end that way.
When Insurance Becomes the Gatekeeper of Survival
According to Morgenson, insurers are increasingly overruling oncologists, rejecting treatments that follow standard cancer care, and delaying care until it is too late.
The recommended surgery in Pike’s case followed guidelines from the National Comprehensive Cancer Network. Yet Blue Cross relied on a doctor reviewer who is not an oncologist. The insurer labeled the surgery as not medically necessary.
“Would he have lived?” Tracy’s widow, Shonna Pike, asked. “I don’t know. But I think he would have had a shot.”
The Numbers Tell a Broader Story
Pike’s loss is not unique. Millions of Americans face denials of necessary care, especially for cancer. Evidence shows this:
– In 2023, nearly 50 million prior authorization requests flooded Medicare Advantage insurers.
– Of those denied, only 11.7 percent were appealed. Yet over 80 percent of those appeals were at least partially overturned.
– The American Society of Clinical Oncology found that 14 percent of delayed cancer treatments due to prior authorization caused serious harm, and 36 percent caused loss of life.
– A study in JAMA Network Open showed that 22 percent of cancer patients never received prescribed treatment because of insurer delays or denials.
These figures show how much is at stake when an insurer’s decision goes unchallenged.
What You Can Do and What You Deserve to Know
If your insurer denies the care your doctor recommends, an appeal may be possible. The process depends on the type of health insurance you have. Knowing your rights and your plan’s rules can significantly impact the outcome and timing of your care.
Appeals are not guaranteed to succeed. Based on the data, they frequently do. An appeal often becomes the crucial step that leads to granted coverage.
Based on the data, they frequently do. An appeal often becomes the crucial step that leads to granted coverage.
Medicare Advantage (Part C) Plans
You can start with an internal appeal. If that fails, you can ask for an external review by a Medicare-appointed reviewer. You may then appeal further, including asking for a hearing before an administrative law judge.
In 2023, over 80 percent of appealed denials were at least partially reversed. But fewer than 12 percent of denials were appealed. This statistic indicates that many eligible recipients fail to exercise their rights.
Employer-Sponsored Plans (ERISA)
For private employer plans administered under ERISA, you must first file an internal appeal. If that fails, you may sue in federal court.
ERISA gives insurers broad discretion. Courts can defer to their decisions unless they are arbitrary and capricious. Jury trials are not available, and remedies are limited to the denial of the benefit. Still, a timely and well-documented appeal can result in a reversal.
ACA Marketplace or Direct-to-Consumer Plans
If your plan came from HealthCare.gov or was purchased directly and is not employer-sponsored, ACA and state rules apply. These plans must provide internal appeal options, independent external review, and access to your state insurance department.
In Kentucky and Ohio, state-supervised external reviews are binding. With medical evidence, clinical guidelines, and doctors’ support letters, patients improve their chances of success. These plans offer stronger consumer protections than ERISA plans.
Short-Term or Limited Benefit Plans
Some short-term or limited-duration plans are not subject to ERISA or the ACA regulations. Their appeal rights may be narrower. External reviews may not apply.
That does not mean you have no options. Some insurers reverse decisions when challenged with strong documentation. State consumer protection laws may still offer help. It can be worth submitting an appeal.
Clarity, Not Certainty
I cannot guarantee success in any appeal. But I can promise clarity. You deserve to understand the rules of your plan and your appeal rights. A transparent process and timely documentation often make the difference.
Appeals can succeed. They often do. When they do not, they can lead to external review, financial aid, or legal recourse. The key is to act promptly and not go through this alone.
Honoring Tracy Pike
Tracy Pike deserved the benefit of fair medical judgment. His doctors saw hope. His family believed in it. But his insurer said no. What happened to Tracy Pike and his family is not merely one man’s story. It represents every patient’s struggle for the care they deserve.
If your insurer has denied medically necessary care and you’re unsure what to do, reach out to AppealHealthcare.com. We can help. If you are in Kentucky or Ohio, you don’t have to face this alone.
Sources
- Gretchen Morgenson, “‘Would He Have Lived?’ When Health Insurance Companies Deny Cancer Care to Patients,” NBC News (December 27, 2024), https://www.nbcnews.com/news/investigations/-lived-health-insurance-companies-deny-cancer-care-patients-rcna182611.
- American Society of Clinical Oncology, “Survey on Prior Authorization and Cancer Care,” referenced in Morgenson, supra note 1.
- KFF, “Nearly 50 Million Prior Authorization Requests Were Sent to Medicare Advantage Insurers in 2023,” KFF Issue Brief (January 28, 2025), https://www.kff.org/medicare/issue-brief/nearly-50-million-prior-authorization-requests-were-sent-to-medicare-advantage-insurers-in-2023.
- Alexandra R. Sokol, M.P.H., et al., “Association of Prior Authorization and Delays in Cancer Treatment,” JAMA Network Open (2024), referenced in Morgenson, supra note 1.
